ArticleOncology letters2025

Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation.

Jiajie Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.